Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.
Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.
Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.
RU58841 is used for hair loss, with some users reporting decreased shedding and preserved hairlines. Concerns about safety and side effects like heart issues are noted, and some combine it with finasteride and minoxidil for better results.
There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.
The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.
The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.
A 16-year-old is experiencing hair thinning and has been using 5% minoxidil for three months and finasteride for one month. They are considering adding dutasteride but are concerned about potential side effects like prostate cancer.
The user had a successful hair transplant with 4,000 grafts and uses 0.5 mg oral dutasteride and topical minoxidil to maintain results. They report minimal side effects and are pleased with the outcome.
A case study that suggests verteporfin may be able to help regrow donor hairs after FUE extraction, and the potential implications of this result. Treatments discussed include Minoxidil, Finasteride, and RU58841.
The conversation discusses using RU58841, topical finasteride/minoxidil, MK677, and microneedling as treatments for hair loss. MK677 is mentioned as a growth hormone that improves hair health and recovery from microneedling.
The conversation discusses hair loss treatments, specifically topical dutasteride, minoxidil, and finasteride. Users share experiences and opinions on the effectiveness and side effects of these treatments.
User considers adding Alfatradiol to their topical finasteride treatment for hair loss. Others discuss Alfatradiol as a weak estrogen and 5α-reductase inhibitor used for pattern hair loss in men and women.
PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.
The conversation is about a person's hair improvement after 14.5 months using RU58841 and Minoxidil topically at 50 mg each day, with noticeable hairline improvement but incomplete crown area recovery. The person struggles to take good pictures of their crown area.
Alternating between finasteride and dutasteride is being considered due to cost concerns. The user is worried about losing progress if switching entirely to dutasteride.
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
RU58841, oral and topical minoxidil, finasteride, and ketoconazole shampoo led to significant hair regrowth, though some suspect a hair transplant. Concerns about RU58841's side effects, like anxiety and heart issues, were discussed.
A 35-year-old male has been using finasteride inconsistently for two years and is hesitant about using minoxidil due to potential side effects. He is considering oral minoxidil and microneedling as alternatives and is unsure if dutasteride is too strong.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.
A user named "tresslessinseattle" receiving a mysterious package of Eucapil hair loss treatment, which they are considering in combination with Minoxidil and Finasteride treatments to boost the regrowth they have been seeing.
A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.
A user created a free AI-powered hair transplant simulator to help visualize post-transplant results, seeking feedback and offering it as a tool for clinics. Users discussed its usefulness, limitations, and the requirement for email and phone verification to prevent abuse.
The conversation is about an 18-year-old's progress with hair regrowth using oral Minoxidil, dermarolling, and RU58841 over three months, starting treatment after beginning to lose hair at 16. Participants are impressed with the improvement and encourage continued treatment.